Zeo ScientifiX, Inc.
ZEOX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZEOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZEOX
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases and regenerative medicine, primarily through its proprietary products Zofin™ and Patient Pure X™.
Key risk: FDA regulatory uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Apr 30, 2026.
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases and regenerative medicine, primarily through its proprietary products Zofin™ and Patient Pure X™.
- Zeo ScientifiX is a clinical-stage biopharmaceutical company developing innovative biological therapeutics for degenerative diseases and regenerative medicine [sec_mda · as of 2025-06-16].
- The company's proprietary products include Zofin™, derived from perinatal sources, and Patient Pure X™ (PPX™), an autologous biologic from a patient's own blood [sec_mda · as of 2025-06-16].
- As of April 30, 2026, the company reported cash & equivalents of $1.8M, total revenue of $2.6M, net income of -$0.1M, shareholders' equity of -$1.7M, and total debt of $0.5M [sec].
- The company has not obtained an FDA opinion or ruling on whether its current products fall under Section 351 HCT/P regulations, creating regulatory uncertainty [sec_mda · as of 2026-01-29].
- Zeo ScientifiX has been unsuccessful in achieving a stabilized source of revenues despite efforts since July 2015, and relies on additional investment capital to fund operations [sec_mda · as of 2025-09-15].
What works
- The company is actively pursuing clinical trials, international sales expansion, and new product offerings to mitigate regulatory risks and diversify revenue streams [sec_mda · as of 2026-06-15].
- Zeo ScientifiX has generated $2.6M in total revenue as of April 30, 2026, indicating some commercial activity despite ongoing challenges [sec].
- The company's products are derived from perinatal sources and autologous blood, which may offer unique therapeutic properties in regenerative medicine [sec_mda · as of 2025-06-16].
What to weigh
- The company faces significant regulatory uncertainty as it has not obtained an FDA opinion on whether its products are subject to HCT/P enforcement policies, which could restrict U.S. sales [sec_mda · as of 2026-01-29].
- Zeo ScientifiX has a shareholders' deficit of -$1.7M as of April 30, 2026, indicating accumulated losses exceeding equity [sec].
- The company has limited cash reserves ($1.8M) and no assets to pledge for borrowing, making future funding potentially costly and dilutive [sec_mda · as of 2026-03-17].
- Despite efforts since July 2015, the company has not achieved a stabilized source of revenues, raising going-concern risks [sec_mda · as of 2025-09-15].
From the filings
Quoted directly from source documents.
The company has not obtained an FDA opinion on product classification under HCT/P regulations.
“The Company has not obtained any opinion or ruling regarding the Company's operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA's previously announced intended enforcement policies regarding HCT/P's.”
SEC MD&A · January 29, 2026
The company has been unable to achieve stabilized revenues since July 2015.
“despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues.”
SEC MD&A · September 15, 2025
Future funding is expected to be costly and dilutive due to market capitalization and liquidity constraints.
“The Company's current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all.”
SEC MD&A · June 15, 2026
The company is a clinical-stage biopharmaceutical firm focusing on degenerative diseases and regenerative medicine.
“We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine.”
SEC MD&A · June 16, 2025
Risks & what to watch (4)›
Key risks
- FDA regulatory uncertainty — No FDA opinion on whether products fall under HCT/P enforcement policies, which could restrict U.S. sales [sec_mda · as of 2026-01-29].
- Going concern risk — Shareholders' deficit of -$1.7M and reliance on additional capital to fund operations [sec].
- Limited funding sources — No assets to pledge for borrowing; equity raises may be costly and dilutive [sec_mda · as of 2026-03-17].
- Revenue instability — Unsuccessful in achieving stabilized revenues since July 2015 [sec_mda · as of 2025-09-15].
What to watch
- FDA regulatory actions or rulings on HCT/P classification of the company's products [sec_mda · as of 2026-01-29].
- Progress in clinical trials and international sales expansion as part of risk mitigation [sec_mda · as of 2026-06-15].
- Ability to raise additional capital through debt or equity, given limited cash reserves and market constraints [sec_mda · as of 2026-03-17].
- Trends in quarterly revenue and net income to assess progress toward stabilized revenues [sec].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Zeo ScientifiX, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zeo ScientifiX, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
49.4 months
D/E 4.46 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Frequently asked questions
What is the AI investment thesis for Zeo ScientifiX, Inc.?
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases and regenerative medicine, primarily through its proprietary products Zofin™ and Patient Pure X™.
Who is the CEO of Zeo ScientifiX, Inc.?
Mr. Ian T. Bothwell is the chief executive officer of Zeo ScientifiX, Inc. (ZEOX).
Where is Zeo ScientifiX, Inc. headquartered?
Zeo ScientifiX, Inc. (ZEOX) is headquartered in Davie, FL, United States.
What therapeutic areas does Zeo ScientifiX, Inc. focus on?
Zeo ScientifiX, Inc. develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.